Forma Therapeutics Holdings, Inc.
FMTXDelisted- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001538927
Forma Therapeutics Holdings, Inc. was delisted in 2022; its insiders filed their last Form 4 on Oct 14, 2022; 139 institutions reported holding it in 13F filings for Q3 2022, worth $836.5M in total; HHLR Advisors (Hillhouse) was the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Forma Therapeutics Holdings, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Forma Therapeutics Holdings, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| RA Capital Healthcare Fund LP | 10% Owner | 0Indirect | Oct 14, 2022 | 0 |
| Ra Capital Management, L.P. | Director, 10% Owner | 0Indirect | Oct 14, 2022 | 0 |
| Kolchinsky Peter | 10% Owner | 0Indirect | Oct 14, 2022 | 0 |
| Shah Rajeev M. | 10% Owner | 0Indirect | Oct 14, 2022 | 0 |
| Wirth Peter | Director | 0 | Oct 14, 2022 | 0 |
| Wiggans Thomas G | Director | 0 | Oct 14, 2022 | 0 |
| Clackson Timothy P | Director | 0 | Oct 14, 2022 | 0 |
| Fanucci Marsha | Director | 0 | Oct 14, 2022 | 0 |
| Bishop John E | SVP, Chief Technology Officer | 0 | Oct 14, 2022 | 0 |
| Molina Arturo MD | Director | 0 | Oct 14, 2022 | 0 |
| Shegog Todd | SVP, Chief Financial Officer | 0 | Oct 14, 2022 | 0 |
| Frederick Wayne A.I. | Director | 0 | Oct 14, 2022 | 0 |
| Lee Frank D. | President and CEO | 0 | Oct 14, 2022 | 0 |
| Potts Jeannette | See Remarks | 0 | Oct 14, 2022 | 0 |
| Melian Agustin | EVP, Research & Development | 0 | Oct 14, 2022 | 0 |
| Lesser Brian Andrew | SVP, Commercial Officer | 0 | Oct 14, 2022 | 0 |
| Vickers Selwyn M MD | Director | 7,250 | Jun 9, 2022 | 0 |
| Kelly Patrick F. | SVP, Chief Medical Officer | 104,884 | Apr 14, 2022 | 0 |
| Cook David N | SVP, Chief Scientific Officer | 41,469 | Mar 2, 2022 | 0 |
| Wadlinger Mary E. | See Remarks | 134,521 | Feb 25, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2022 (view filing) | Feb 23 | 2 days | Cook David NSVP, Chief Scientific Officer | SSale | −3.53K | $9.78 | −$34.5K | −17.7%16.5K after | |
| Feb 25, 2022 (view filing) | Feb 23 | 2 days | Lee Frank D.President and CEO | SSale | −18.0K | $9.78 | −$175.9K | −18.4%79.8K after | |
| Feb 25, 2022 (view filing) | Feb 23 | 2 days | Kelly Patrick F.SVP, Chief Medical Officer | SSale | −5.25K | $9.78 | −$51.3K | −7.5%64.9K after | |
| Feb 25, 2022 (view filing) | Feb 23 | 2 days | Shegog ToddSVP, Chief Financial Officer | SSale | −5.69K | $9.78 | −$55.6K | −20.0%22.8K after | |
| Feb 25, 2022 (view filing) | Feb 23 | 2 days | Lesser Brian AndrewSVP, Commercial | SSale | −3.84K | $9.78 | −$37.5K | −17.9%17.6K after | |
| Feb 25, 2022 (view filing) | Feb 23 | 2 days | Wadlinger Mary E.See Remarks | SSale | −4.68K | $9.78 | −$45.8K | −3.4%134.5K after | |
| Feb 25, 2022 (view filing) | Feb 23 | 2 days | Potts JeannetteSee Remarks | SSale | −4.67K | $9.78 | −$45.7K | −17.3%22.4K after |